A Retrospective Study of the Effects of Pemafibrate in Patients with Dyslipidemia Complicated by Metabolic Dysfunction-Associated Steatotic Liver Disease

A Retrospective Study of the Effects of Pemafibrate in Patients with Dyslipidemia Complicated by Metabolic Dysfunction-Associated Steatotic Liver Disease - A Retrospective Observational Study Investigating the Effects of Pemafibrate in Patients with Dyslipidemia Complicated by Metabolic Dysfunction-Associated Steatotic Liver Disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061398

Enrollment

495

Registered

2026-04-28

Start date

2026-01-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with dyslipidemia complicated by steatotic liver disease/MASLD

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with dyslipidemia complicated by fatty liver disease/MASLD who attended the participating medical institution during the study period, received pemafibrate, and for whom the presence or absence of impaired glucose tolerance can be confirmed. Patients whose required data items, as described below, are recorded in the electronic medical records.

Exclusion criteria

Exclusion criteria: Patients for whom the required data items cannot be collected from the medical records.

Design outcomes

Primary

Measure	Time frame
Change in FAST score by impaired glucose tolerance status	—

Secondary

Measure	Time frame
Vibration-controlled transient elastography, controlled attenuation parameter, and FAST score measured using FibroScan; lipid parameters, including triglycerides, total cholesterol, HDL cholesterol, and LDL cholesterol; glucose metabolism-related parameters, including blood glucose and HbA1c; fatty liver/MASLD-related parameters, including body weight, AST, ALT, G-GTP, ALP, total bilirubin, albumin, prothrombin time, platelet count, FIB-4 index, and APRI; and renal function-related parameters, including BUN, creatinine, and eGFR.	—

Measure

Time frame

Vibration-controlled transient elastography, controlled attenuation parameter, and FAST score measured using FibroScan; lipid parameters, including triglycerides, total cholesterol, HDL cholesterol, and LDL cholesterol; glucose metabolism-related parameters, including blood glucose and HbA1c; fatty liver/MASLD-related parameters, including body weight, AST, ALT, G-GTP, ALP, total bilirubin, albumin, prothrombin time, platelet count, FIB-4 index, and APRI; and renal function-related parameters, including BUN, creatinine, and eGFR.

—

Countries

Japan

Contacts

Public Contactkensaku fukunaga

Kagawa university Department of Endocrinology and Metabolism

fukunaga.kensaku@kagawa-u.ac.jp0878912230

Outcome results